NJ A2864

Permits terminally ill patients (life expectancy of 12 months or less) to access investigational drugs, biological products, and devices that have completed FDA phase one clinical trials but are not yet fully approved.

Requires hospitals to provide and administer FDA-approved drugs, biological products, or devices for off-label uses upon request from eligible terminally ill patients, even if not part of the hospital's standard treatment protocols.

Patients must obtain a prescription or recommendation from a licensed New Jersey physician, provide written informed consent, and consider all FDA-approved treatment options before accessing investigational or off-label treatments.

Provides liability protection for physicians, hospitals, and healthcare staff assisting with these treatments, except in cases of gross negligence, recklessness, or willful misconduct.

Makes it a disorderly persons offense (punishable by up to 6 months imprisonment and/or $1,000 fine) for government officials to block eligible patients' access to these treatments.